Group 1 - The medical beauty sector increased by 0.06% on January 19, with Jinbo Biological leading the gains [1] - The Shanghai Composite Index closed at 4114.0, up 0.29%, while the Shenzhen Component Index closed at 14294.05, up 0.09% [1] - Jinbo Biological's closing price was 238.79, with a rise of 1.61%, while other companies like Aimeike and Huaxi Biological showed mixed performance [1] Group 2 - The medical beauty sector experienced a net outflow of 808.89 million yuan from main funds, while retail investors saw a net inflow of 5.19 million yuan [1] - Aimeike had a main fund net inflow of 16.01 million yuan, but also faced significant outflows from retail and speculative funds [2] - Jinbo Biological saw a main fund net inflow of 10.08 million yuan, with a notable retail net inflow of 4.28 million yuan [2]

Core Insights - The announcement of the first batch of "Biomanufacturing Pilot Capability Construction Platform List" by the Ministry of Industry and Information Technology highlights Huaxi Biological Technology (Tianjin) Co., Ltd. as a leading player, achieving the highest "five-star" rating and being one of only five such units in the country [1] - The recognition emphasizes the importance of pilot platforms in bridging the gap between research and industrialization in biomanufacturing, addressing the low technology transfer rate in China compared to developed countries [1][2] Group 1: Company Achievements - Huaxi Biological has invested over 3 billion yuan to create the world's largest synthetic biology pilot transformation platform, featuring 64 pilot production lines across a 40,000 square meter facility [2] - The platform supports the scale-up of six categories of bioactive substances, serving multiple strategic emerging industries including pharmaceuticals, cosmetics, and functional foods [2][3] Group 2: Industry Context - The pilot platform is crucial for overcoming the challenges of scaling up from laboratory to industrial production, addressing issues such as process optimization, quality control, and cost accounting [2] - The Chinese government aims to cultivate over 20 biomanufacturing pilot platforms by 2027, recognizing biomanufacturing as a key aspect of the Fourth Industrial Revolution, with a projected global market size exceeding $390 billion by 2030 [3][4] Group 3: Collaborative Efforts - The pilot transformation platform is designed to be an industry-level infrastructure, providing comprehensive services to universities and startups, thus promoting the integration of government, industry, academia, research, finance, and application [4] - Huaxi Biological aims to enhance the overall capabilities of China's biomanufacturing sector through collaboration and the development of a robust platform ecosystem [4]

Investment Rating - Investment rating: Positive (maintained) [1] Core Insights - The luxury goods retail revenue in China is showing signs of recovery, with high-end brands like LVMH, Hermès, and Prada experiencing positive growth since Q2 2025 [15][16] - The global network literature market is witnessing rapid growth, particularly in Latin America, with WebNovel reaching nearly 400 million cumulative users by October 2025 [34][35] - The micro-drama and comic-drama market in China is projected to exceed 100 billion yuan in 2025, significantly surpassing the film box office revenue [37][38] - The probiotic market is expanding, with a focus on next-generation probiotics (NGPs) like AKK bacteria, which show significant potential in health applications [55][63] Summary by Sections 1. Duty-Free Shopping - Post-New Year duty-free shopping in Hainan shows strong growth, with sales reaching 3.89 billion yuan and a 49.6% year-on-year increase in shopping amount [31][33] - The high net worth individuals are expected to drive luxury consumption, with a notable increase in spending on preservation-type luxury goods [15][16] 2. Network Literature - The Chinese network literature market reached 49.55 billion yuan in 2024, with a 29.37% year-on-year growth, while the overseas market grew by 10.68% [34] - WebNovel has cultivated nearly 530,000 authors and over 820,000 original works, with a significant increase in user engagement [34][35] 3. Micro-Drama - The micro-drama and comic-drama market in China is expected to reach 100 billion yuan in 2025, with a 98% year-on-year growth [37][38] - The user base for micro-dramas is approaching 700 million, with a strong preference among female viewers [40][42] 4. Probiotics - The global probiotic market is projected to grow at a CAGR of 8.7%, reaching 93.49 billion USD by 2028, with China's market expected to reach 134.89 billion yuan by 2024 [55][63] - Next-generation probiotics like AKK bacteria are gaining traction, with significant potential in health management and consumer interest [55][63]

Group 1 - The major shareholder, Guoshou Chengda, held 28,936,504 shares of Huaxi Biological Technology Co., Ltd., accounting for 6.01% of the total share capital before the reduction plan [2] - The reduction plan involved a maximum of 9,633,564 shares, representing up to 2.00% of the total share capital, with a maximum of 4,816,782 shares to be reduced through both centralized bidding and block trading [3] - As of January 15, 2026, Guoshou Chengda completed the reduction of 9,633,564 shares, with 4,816,782 shares reduced through centralized bidding and 4,816,782 shares through block trading [3][5] Group 2 - The reduction plan was disclosed on November 5, 2025, and the reduction period was set from November 26, 2025, to February 23, 2026 [3] - The actual reduction adhered to relevant laws and regulations, and there were no violations of the reduction plan or other commitments [6]

证券代码：688363 证券简称：华熙生物 公告编号：2026-002 华熙生物科技股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持有的基本情况 本次减持计划实施前，国寿成达（上海）健康产业股权投资中心（有限合伙） （以下简称"国寿成达"）直接持有华熙生物科技股份有限公司（以下简称"公司"） 股份数量为 28,936,504 股，占公司总股本的 6.01%。上述股份全部为公司首次公 开发行前股份，并已于 2022 年 11 月 7 日起上市流通。 减持计划的实施结果情况 公司于 2025 年 11 月 5 日在上海证券交易所网站（www.sse.com.cn）披露《华 熙生物科技股份有限公司股东减持股份计划公告》（公告编号：2025-043），国寿 成达计划根据市场情况通过集中竞价、大宗交易的方式减持其所持有的公司股份 合计不超过 9,633,564 股，拟减持股份数量占公司总股本的比例合计不超过 2.00%， 其中以集中竞价方式减持比例不超过 1.0 ...

格隆汇1月16日丨华熙生物(688363.SH)公布，截至2026年1月15日，国寿成达以集中竞价方式减持公司 股份481.68万股，以大宗交易方式减持公司股份481.68万股，合计减持公司股份963.36万股，减持计划 已实施完毕。 ...

Market Overview - The medical beauty sector experienced a decline of 1.79% on January 16, with Huaxi Biological leading the drop [1] - The Shanghai Composite Index closed at 4101.91, down 0.26%, while the Shenzhen Component Index closed at 14281.08, down 0.18% [1] Individual Stock Performance - Jinbo Biological (920982) closed at 235.00, with a slight increase of 0.38% and a trading volume of 6758.42 lots [1] - ST Meigu (000615) closed at 3.43, up 0.29% with a trading volume of 12.66 million [1] - Aimeike (300896) closed at 146.31, down 1.68% with a trading volume of 35,000 [1] - Huaxi Biological (688363) closed at 46.31, down 2.24% with a trading volume of 51,600 [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 112 million yuan from main funds, while retail investors contributed a net inflow of 73.41 million yuan [1] - The detailed capital flow for individual stocks shows: - ST Meigu had a main fund net outflow of 446,500 yuan and a retail net inflow of 198,200 yuan [2] - Jinbo Biological experienced a main fund net outflow of 7.88 million yuan and a retail net outflow of 223,700 yuan [2] - Huaxi Biological had a significant main fund net outflow of 46.59 million yuan, with retail investors contributing a net inflow of 27.27 million yuan [2] - Aimeike faced a main fund net outflow of 64.99 million yuan, while retail investors had a net inflow of 45.95 million yuan [2]

直面"死亡之谷"：科技成果转化的中国困境与破局关键 在生物制造领域，"死亡之谷"是业界对科研成果从实验室走向市场应用过程中，一道难以逾越的产业化 鸿沟的形象比喻。 日前，工业和信息化部首批《生物制造中试能力建设平台名单》公示落下帷幕。在这场关乎国家未来产 业竞争力的权威评选中，华熙生物科技（天津）有限公司凭借全球规模领先的合成生物中试平台脱颖而 出，不仅成功入选，更获评最高"五星"等级。尤为引人注目的是，该公司在化妆品、食品添加剂、生物 制药三大核心领域同时斩获最高认证，成为全国仅有的5家五星单位之一。 这枚"五星"认证，不仅是对一家企业技术实力的肯定，更让长期隐身于产业幕后的"中试平台"这一生物 制造领域的关键基础设施进入公众视野。在我国科技成果转化率仅约10%的产业背景下，这座平台为何 能成为跨越科研与产业化"死亡之谷"的核心力量？ 天津中合基因科技有限公司的案例极具说服力。该公司一项关于"关键酶"的研发在完成实验室小试后， 因无力承担上千万元的中试线建设成本而陷入停滞。入驻华熙生物中试转化平台后，仅用一个月便完成 了工艺放大测试，成本较自建缩减了90%，成功跨越了产业化的最关键一道坎。 超越企业边界：构 ...

Core Viewpoint - Huaxi Biological experienced a stock price decline of 2.01% on January 16, with a trading price of 46.42 yuan per share and a total market capitalization of 22.36 billion yuan [1] Group 1: Stock Performance - Since the beginning of the year, Huaxi Biological's stock price has increased by 6.27%, with a 0.41% rise over the last five trading days and a 6.10% increase over the last 20 days, while it has decreased by 13.56% over the last 60 days [2] - As of November 20, the number of shareholders for Huaxi Biological is 30,100, a decrease of 0.62% from the previous period, with an average of 16,014 circulating shares per person, which is an increase of 0.62% [2] Group 2: Financial Performance - For the period from January to September 2025, Huaxi Biological reported a revenue of 3.163 billion yuan, a year-on-year decrease of 18.36%, and a net profit attributable to shareholders of 252 million yuan, down 30.29% year-on-year [2] - The company has distributed a total of 1.138 billion yuan in dividends since its A-share listing, with 528 million yuan distributed over the past three years [3] Group 3: Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Huaxi Biological include several ETFs, with notable reductions in holdings: E Fund's Shanghai Stock Exchange Science and Technology Innovation Board 50 ETF decreased by 1.0136 million shares, while Huaxia's ETF decreased by 0.38234 million shares [3] - Other significant shareholders also saw reductions, including Hong Kong Central Clearing Limited, which decreased its holdings by 0.31229 million shares [3]

华熙生物1月15日大宗交易平台出现一笔成交，成交量65.00万股，成交金额2830.75万元，大宗交易成交 价为43.55元，相对今日收盘价折价8.06%。该笔交易的买方营业部为机构专用，卖方营业部为中国国际 金融股份有限公司北京建国门外大街证券营业部。 进一步统计，近3个月内该股累计发生51笔大宗交易，合计成交金额为2.04亿元。 据天眼查APP显示，华熙生物科技股份有限公司成立于2000年01月03日，注册资本48167.8242万人民 币。（数据宝） 1月15日华熙生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢价（%） | 业部 | | | 65.00 | 2830.75 | 43.55 | -8.06 | 机构专 | 中国国际金融股份有限公司北京建国 | | | | | | 用 | 门外大街证券营业部 | （文章来源：证券时报网） 证券时报·数据宝统计显示，华熙生物今日收盘价为47.37元，下跌0.17%，日换手率为0 ...